ACTH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-06 and is reviewed periodically as new material appears.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Free acid form of the heptapeptide; depends on terminal groups |
| Molecular mass | About 813.9 g/mol | Average mass used for mass spectrometry confirmation |
| Appearance | White to off-white solid | Supplied as a lyophilised powder; hygroscopic |
| Solubility class | Freely soluble in aqueous media | Water, saline, and phosphate buffers; limited organic solubility |
| Typical storage temperature | -20 degrees Celsius | Long term and dry; short working periods may use 2 to 8 degrees Celsius |
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Since the 18th century, critics have argued that slavery hinders technological advancement because the focus is on increasing the number of slaves doing simple tasks rather than upgrading their efficiency. For example, it is sometimes argued that, because of this narrow focus, technology in Greece – and later in Rome – was not applied to ease physical labour or improve manufacturing.
Sick benefits were administered by the subordinate lodges. In 1899 it was limited to the United States and had 3,000 men and 2,500 women members. The orders seal was a spread eagle with a shield holding an American flag and the words "Liberty, Equality, Fraternity" emblazoned on it. Independent Order of B'nai B'rith Independent Order of B'rith Sholom - Founded in 1905 to assist Jewish immigrants to the US. As Jewish immigration increased, it became more of a human rights organization. Membership open to Jews and gentiles over 16. Female auxiliary named B'rith Sholom Women. Had 52,596 members in 1917. Had 20,000 members in 1979. 6,000 members in 1988. Headquarters in 1917 was at 510-512 5th Street, Philadelphia. Headquarters still at Philadelphia in 1979, when the order had 130 lodges and three statewide organizations. They had a secret ritual, but it was only used by a few lodges. Offers scholarships. Did not have an insurance fund, per se, but offered death and burial benefits and financial aid when members were in need; also taught English language and Americanization. The group saved 50 children aged 5 to 14 during the Holocaust; these were housed at a Camp Sholom. Operates a retirement home in Philadelphia that housed 500. Sponsors Albert Einstein College of Medicine at Yeshiva University and a recuperation center for Israeli soldiers in Haifa. Contributed a 65-acre (26 ha) tract of land for Eagleville Sanatorium.
=== Treatment === Treatment modalities generally include both pharmacological and non-pharmacological, depending on the primary diagnosis. Additional treatment options include referral to specialist care including physical therapy and rehabilitation. Treatment recommendations differ in the acute inpatient and outpatient settings. Continuity of care and long-term follow-up is crucial in successful patient outcomes.
Sources: en.wikipedia.org
30 August – The Electoral Commission submitted its Constituency Review Report 2023 to the Oireachtas. It recommended that the number of Teachtaí Dála be increased from 160 to 174, and that the number of Dáil constituencies be increased from 39 to 43. The increases take account of a population rise of 8% since 2016.
Colloidal gold is a sol or colloidal suspension of nanoparticles of gold in a fluid, usually water. The colloid is coloured usually either wine red (for spherical particles less than 100 nm) or blue-purple (for larger spherical particles or nanorods). Due to their optical, electronic, and molecular-recognition properties, gold nanoparticles are the subject of substantial research, with many potential or promised applications in a wide variety of areas, including electron microscopy, electronics, nanotechnology, materials science, and biomedicine. The properties of colloidal gold nanoparticles, and thus their potential applications, depend strongly upon their size and shape. For example, rodlike particles have both a transverse and longitudinal absorption peak, and anisotropy of the shape affects their self-assembly.
The deportees were released on 19 December and allowed to travel to Cairo and then, with Jamal Husseini, to Beirut where a new Arab Higher Committee (or Higher National Committee) was established. Amin al-Husayni was not a member of the Arab delegation but the delegation was clearly acting under his direction. The London Conference commenced on 7 February 1939, but the Arab delegation refused to sit in the same room with the Jewish delegation present, and the conference broke up in March with no success. In May 1939, the British government presented its 1939 White Paper which was rejected by both sides. The White Paper had, in effect, repudiated the Balfour Declaration. According to Benny Morris, Amin al-Husayni "astonished" the other members of the Arab Higher Committee by turning down the White Paper. Al-Husayni turned the advantageous proposal down because "it did not place him at the helm of the future Palestinian state." The deportees were not allowed to return to Palestine until 1941. Amin Al-Husayni spent the war years in occupied Europe, actively collaborating with the Nazi leadership. Amin and Jamal al-Husayni were involved in the 1941 pro-Nazi Rashidi revolt in Iraq. Amin again evaded capture by Britain but Jamal was captured in 1941 and interned in Southern Rhodesia, where he was held until November 1945 when he was allowed to move to Cairo. Husayn al-Khalidi returned to Palestine in 1943. Jamal al-Husayni returned to British Palestine in February 1946 as an official of the new Arab Higher Committee, by then recognised by the Mandate administration.
Sources: en.wikipedia.org
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.
It appears in Russian pharmaceutical listings as a nasal formulation, but it is not an authorised medicine in the United States or the European Union. Outside those markets it is normally encountered as a research chemical rather than a prescription product.
Laboratory and animal work points to melanocortin signalling and changes in neurotrophic factor levels, especially brain-derived neurotrophic factor. The exact receptor targets and the degree to which these findings transfer to humans are still unresolved.
It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.